Rezzayo Injection, Powder, Lyophilized, For Solution
Product Images NDC 70842-240

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Rezzayo (NDC 70842-240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Melinta Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Carton (package principal panel)

REZZAYO 200 mg per vial injection label for rezafungin. The label specifies this lyophilized powder is for intravenous infusion. It notes the vial contains 200 mg of rezafungin (equivalent to 210 mg of rezafungin acetate), requiring reconstitution and dilution. The labeler is Melinta Therapeutics, LLC.*

FDA Label Image

Image Of Chemicalstructure (Fig 01)

Chemical structure of rezafungin depicted as interconnected molecular rings and functional groups, illustrating the detailed arrangement of atoms and bonds characteristic of this antifungal agent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.